UCB’s IL-17 latecomer bimekizumab beats Cosentyx in psoriasis trialBelgian biopharma company UCB is bringing up the rear of the IL-17 inhibitor category with its bimekizumab drug, Share XUCB’s IL-17 latecomer bimekizumab beats Cosentyx in psoriasis trialhttps://pharmaphorum.com/news/ucbs-il-17-latecomer-bimekizumab-beats-cosentyx-in-psoriasis-trial/
Lilly’s mirikizumab tops Novartis’ blockbuster Cosentyx in psoriasisEli Lilly is a latecomer in the new generation of biologic therapies for psoriasis with its mirikizumab candidate, Share XLilly’s mirikizumab tops Novartis’ blockbuster Cosentyx in psoriasishttps://pharmaphorum.com/news/lillys-mirikizumab-tops-novartis-blockbuster-cosentyx-in-psoriasis/
Towards Patient Centricity: LEO PharmaIndustry plays a pivotal role in making sure patient needs are not overlooked by the wider healthcare community. Share XTowards Patient Centricity: LEO Pharmahttps://pharmaphorum.com/views-analysis-patients/towards-patient-centricity-leo-pharma/
UCB’s bimekizumab tops J&J’s Stelara in psoriasis studyThe first phase 3 data with UCB’s key pipeline drug bimekizumab show that it hit all its efficacy Share XUCB’s bimekizumab tops J&J’s Stelara in psoriasis studyhttps://pharmaphorum.com/news/ucbs-bimekizumab-tops-jjs-stelara-in-psoriasis-study/
Amgen stumps up $13.4bn to claim Otezla from CelgeneCelgene has the buyer it needed for Otezla, smoothing the way for its mega-merger with Bristol-Myers Squibb. Amgen Share XAmgen stumps up $13.4bn to claim Otezla from Celgenehttps://pharmaphorum.com/news/amgen-stumps-up-13-4bn-to-claim-otezla-from-celgene/
Novartis ups 2019 guidance after strong Q2Novartis has revised its guidance for 2019 upwards after a strong set of Q2 figures, with its psoriasis Share XNovartis ups 2019 guidance after strong Q2https://pharmaphorum.com/news/novartis-ups-2019-guidance-after-strong-q2/
BMS will shed Otezla to push Celgene takeover throughBristol-Myers Squibb has opted to divest big-selling psoriasis drug Otezla to smooth the passage of its $74 billion Share XBMS will shed Otezla to push Celgene takeover throughhttps://pharmaphorum.com/news/bms-will-shed-otezla-to-push-celgene-takeover-through/
Patient Insights: Severe psoriasis & eczemaHoward Chang has lived with severe psoriasis and atopic dermatitis for almost 40 years since childhood. Now a Share XPatient Insights: Severe psoriasis & eczemahttps://pharmaphorum.com/views-analysis-patients/patient-insights-severe-psoriasis-eczema/
AbbVie gets crucial US approval for psoriasis drug SkyriziWith one eye on life without its ageing $20 billion-a-year blockbuster Humira, AbbVie has got its psoriasis drug Share XAbbVie gets crucial US approval for psoriasis drug Skyrizihttps://pharmaphorum.com/news/abbvie-gets-crucial-us-approval-for-psoriasis-drug-skyrizi/
